Early research (Phase 1)Study completedNCT04583228
What this trial is testing
Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of HLX71 (Recombinant Human Angiotensin-converting Enzyme 2-Fc Fusion Protein for COVID-19) in Healthy Adult Subjects
Who this might be right for
COVID 19
Hengenix Biotech Inc 32